lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-17 and is reviewed periodically as new material appears.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Brincidofovir is one of several experimental drugs administered to a small number of patients to treat Ebola virus disease during the 2014 outbreak. The WHO published a report on the ethics of using unregistered interventions to treat Ebola, where they concluded that "In the particular context of the current Ebola outbreak in West Africa, it is ethically acceptable to offer unproven interventions that have shown promising results in the laboratory and in animal models but have not yet been evaluated for safety and efficacy in humans as potential treatment or prevention."
== History == Leuprorelin was discovered and first patented in 1973 and was introduced for medical use in 1985. It was initially marketed only for daily injection, but a depot injection formulation was introduced in 1989.
=== Types === The conditions included under the term "congenital myopathy" can vary. One source includes nemaline myopathy, myotubular myopathy, central core myopathy, congenital fiber type disproportion, and multicore myopathy. The term can also be used more broadly, to describe conditions present from birth.
==== 2000–2099 ==== Value Added Tax (Payments on Account) Order 1993 (S.I. 1993/2001) Friendly Societies Appeal Tribunal Regulations 1993 (S.I. 1993/2002) Income Tax (Stock Lending) (Amendment) Regulations 1993 (S.I. 1993/2003) Income Tax (Manufactured Overseas Dividends) Regulations 1993 (S.I. 1993/2004) Cereal Seeds Regulations 1993 (S.I. 1993/2005) Beet Seeds Regulations 1993 (S.I. 1993/2006) Oil and Fibre Plant Seeds Regulations 1993 (S.I. 1993/2007) Vegetable Seeds Regulations 1993 (S.I. 1993/2008) Fodder Plant Seeds Regulations 1993 (S.I. 1993/2009) Tuberculosis (Deer) (Amendment) Order 1993 (S.I. 1993/2010) Local Government Superannuation (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/2013) Local Authorities (Capital Finance) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2014) Fishing Boats (Marking and Documentation) (Enforcement) Order 1993 (S.I. 1993/2015) Sea Fishing (Enforcement of Community Control Measures) Order 1993 (S.I. 1993/2016) Food Premises (Registration) Amendment Regulations 1993 (S.I. 1993/2022) Criminal Justice Act 1993 (Commencement No. 2 Transitional Provisions and Savings) (Scotland) Order 1993 (S.I. 1993/2035) Public Trusts (Reorganisation) (Scotland) Regulations 1993 (S.I. 1993/2036) Agricultural Holdings (Units of Production) Order 1993 (S.I. 1993/2037) Agriculture Act 1993 (Commencement No. 1) Order 1993 (S.I. 1993/2038) Agriculture Act 1993 (Specification of Year) (Potato Target Area) Order 1993 (S.I. 1993/2039) International Development Association (Tenth Replenishment) Order 1993 (S.I.
Sources: en.wikipedia.org
== International law == Trump's proposal for Gaza is against international law; the forcible transfer of populations is prohibited. Members of Trump's administration have walked back on elements of the plan on a few occasions, although in one subsequent statement, Trump held firm to his original plan. On 21 February 2025, after opposition from Arab states, Trump said he would "recommend" but not enforce his plan for the American takeover of Gaza and the re-settlement of the Palestinian population. Arab League leaders met in March to create a counter proposal to Trump's plan, which was rejected by the US and Israel due to concerns about the proposed governance of postwar Gaza and other issues. The White House released a statement that Trump stood by his vision of Gaza without Hamas and welcomed additional talks. In July, Netanyahu met with Trump and reiterated support for the plan of relocating Palestinians, saying it was "free choice" if Palestinians wanted to stay or leave. The US and Israel were working to identify cooperating countries for the plan.
=== Transmission === The reason for this increased HBV infection is unknown, because hepatitis B has no clear transmission routes in many people in China, although both neonatal infection and horizontal transmission during early childhood are still the most common routes. During and before the Cultural revolution many of the cases came from re-used needles that were contaminated with HBV.
== History == Finasteride was the first 5-ARI to be introduced for medical use. It was marketed for the treatment of BPH in 1992 and was subsequently approved for the treatment of pattern hair loss in 1997. Epristeride was the second 5-ARI to be introduced and was marketed for the treatment of BPH in China in 2000. Dutasteride was approved for the treatment of BPH in 2001 and was subsequently approved for pattern hair loss in South Korea in 2009 and in Japan in 2015. The patent protection on finasteride and dutasteride has expired and both drugs are available as generic medications.
Sources: en.wikipedia.org
Indigo dye is a dark blue crystalline powder that sublimes at 390–392 °C (734–738 °F). It is insoluble in water, alcohol, or ether, but soluble in DMSO, chloroform, nitrobenzene, and concentrated sulfuric acid. The chemical formula of indigo is C16H10N2O2. The molecule absorbs light in the orange part of the spectrum (λmax=613 nm). The compound owes its deep color to the conjugation of the double bonds, i.e. the double bonds within the molecule are adjacent and the molecule is planar. In indigo white, the conjugation is interrupted because the molecule is non-planar.
=== Pharmacokinetics === The pharmacokinetic characteristics of reslizumab are similar across the children and adults. Peak serum concentrations are observed at the end of infusion and declines in a biphasic manner. The mean observed accumulation ratio of reslizumab following multiple doses of administration ranged from 1.5 to 1.9-fold. Reslizumab has a volume of distribution of approximately 5 L, clearance of approximately 7 mL/hour, and a half-life of about 24 days. Reslizumab is degraded by enzymatic proteolysis into small peptides and amino acids, as are other monoclonal antibodies.
John Scudder Sr., established the Christian Medical College and Hospital in Vellore in 1900, which has since become one of India's leading medical institutions. The Scudder family's enduring commitment to healthcare and education has left a lasting impact on India's social and medical landscape, inspiring generations of missionaries and healthcare professionals. The YMCA played a significant role in encouraging the development of sport in the princely states, as well as helping to improve agricultural output in rural areas.
=== Symptoms === Pain Paresthesia Spasticity, Hypertonia Muscular Dysfunction or Weakness Radiculopathy Although Tarlov Cysts can develop anywhere along the spine, they are most commonly symptomatic in the sacrum. Women are more likely to exhibit symptoms. They can also appear in clusters or bilaterally along the spine, thus symptoms can be unilateral, bilateral, or with symptoms more dominant on one side. The cases of reported symptomatic Tarlov cysts ranges from 15% to 30% of the overall reported Tarlov cyst cases, depending on the source of literature. Nevertheless, these cysts are important clinical entities because of their tendency to increase in size over time, potentially causing complications and eroding the surrounding bone tissue.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.